文献速递乳腺癌放疗

局部纯黏液癌乳腺切除术后放疗效果:一项基于人群的研究

Effect of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy: a population-based study.
PubMed 文献 · Radiat Oncol · 2022-07-07

该回顾性队列研究利用SEER数据库纳入1998至2015年间接受乳腺切除术的7832例T1-2N0M0(T≤3 cm)纯黏液癌患者,比较术后放疗与不放疗的乳腺癌特异性生存。中位随访92个月,放疗组15年BCSS为94.39%,非放疗组为91.45%(P<0.001),校正HR为0.64(95%CI 0.49-0.83;P=0.001);倾向评分匹配后结果相似。作者认为术后放疗与乳腺癌死亡风险降低相关,获益幅度可能不大,建议对局部纯黏液癌行术后放疗。

要点

  • 在T1-2N0M0(T≤3 cm)纯黏液癌乳腺切除术后患者中,术后放疗组15年BCSS为94.39%,非放疗组为91.45%(P<0.001)。
  • 校正后放疗组vs非放疗组的BCSS风险比HR为0.64(95%CI 0.49-0.83;P=0.001),倾向评分匹配后HR为0.66(95%CI 0.47-0.92;P=0.014)。
  • 术后放疗使15年乳腺癌死亡风险从7.92%降至6.15%(P=0.039),获益在各亚组中一致。

核心结论

  • 在T1-2N0M0(肿瘤≤3 cm)纯黏液癌女性中,乳腺切除术后加放疗与非放疗相比,与乳腺癌死亡发生率降低显著相关,获益幅度可能不大。
  • 作者认为局部纯黏液癌治疗中推荐术后放疗。

研究设计与样本

  • 回顾性队列研究,利用SEER数据库纳入1998至2015年间接受乳腺切除术的首发原发T1-2N0M0(T≤3 cm)纯黏液癌患者。
  • 共7832例符合条件患者,5352例(68.3%)接受乳腺切除术后放疗,2480例(31.7%)接受乳腺切除但不术后放疗。
  • 采用Kaplan-Meier法和Cox比例风险回归模型比较乳腺癌特异性生存(BCSS),并行倾向评分匹配(PSM)平衡基线,另进行亚组探索性分析验证放疗有效性。

主要发现

  • 中位随访92个月;放疗组中位年龄66岁,非放疗组76岁。
  • 放疗组15年BCSS为94.39%(95%CI 93.08%-95.35%),非放疗组为91.45%(95%CI 88.93%-93.42%)(P<0.001)。
  • 放疗组vs非放疗组校正BCSS的HR为0.64(95%CI 0.49-0.83;P=0.001);倾向评分匹配后放疗组vs非放疗组校正HR为0.66(95%CI 0.47-0.92;P=0.014)。
  • 术后放疗使15年乳腺癌死亡风险从7.92%降至6.15%(P=0.039)。
  • 放疗获益在各亚组患者中一致。

关键数值与推荐

  • 放疗组15年BCSS为94.39%(95%CI 93.08%-95.35%),非放疗组为91.45%(95%CI 88.93%-93.42%)(P<0.001)。
  • 放疗组vs非放疗组校正BCSS的HR为0.64(95%CI 0.49-0.83;P=0.001),倾向评分匹配后HR为0.66(95%CI 0.47-0.92;P=0.014)。
  • 术后放疗使15年乳腺癌死亡风险从7.92%降至6.15%(P=0.039)。

临床怎么用

  • 作者认为对局部纯黏液癌(T1-2N0M0,肿瘤≤3 cm)乳腺切除术后推荐术后放疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pure mucinous breast cancer is a rare subtype of invasive breast cancer with favorable prognosis, in which the effect of postoperative radiotherapy remains unclear. We aimed to investigate the prognostic value of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy. METHODS: We conducted a retrospective cohort study to compare the effectiveness of postoperative radiotherapy (RT) and omitting postoperative radiotherapy (non-RT) in patients with first primary T1-2N0M0 (T ≤ 3 cm) pure mucinous breast cancer who underwent lumpectomy between 1998 and 2015 using the Surveillance, Epidemiology, and End Results (SEER) database. Breast cancer-specific survival (BCSS) was compared between RT and non-RT groups using Kaplan-Meier method and Cox proportional hazards regression model. Propensity score matching (PSM) was carried out to balance cohort baselines. In addition, an exploratory analysis was performed to verify the effectiveness of RT in subgroup patients. RESULTS: Of 7832 eligible patients, 5352 (68.3%) underwent lumpectomy with postoperative RT, 2480 (31.7%) received lumpectomy without postoperative RT. The median follow-up duration was 92 months. The median age was 66 years in the RT group and 76 years in the non-RT group.The 15-year BCSS was 94.39% (95% CI, 93.08% to 95.35%) in the RT group versus 91.45%(95% CI, 88.93% to 93.42%) in the non-RT group (P < 0.001). The adjusted hazard ratio for BCSS was 0.64 (95% CI, 0.49 to 0.83; P = 0.001) for RT group versus non-RT group. After propensity score matching, similar results were yielded. Adjuvant RT reduced the 15-year risk of breast cancer death from 7.92% to 6.15% (P = 0.039). The adjusted hazard ratio for BCSS were 0.66 (95%CI, 0.47 to 0.92; P = 0.014) for RT group versus non-RT group. The benefit of RT was well consistent across subgroup patients. CONCLUSION: Among women with T1-2N0M0 (tumor size ≤ 3 cm) pure mucinous breast cancer, the addition of RT after lumpectomy was significantly associated with a reduced incidence of breast cancer death compared with non-RT, and the magnitude of benefit may be modest. This suggests that postoperative RT is recommended in the treatment of localized pure mucinous breast cancer.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Mo Q, Wang Y, Shan J, et al. Effect of postoperative radiotherapy in women with localized pure mucinous breast cancer after lumpectomy: a population-based study. Radiat Oncol. 2022. PMID: 35799256. doi:10.1186/s13014-022-02082-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。